SCHEDULE: Rosalind Advisors Amends MediWound Stake to 5.2%
Beneficial Ownership Report
Rosalind Advisors and affiliated entities have updated their beneficial ownership in MediWound Ltd. to 5.2% of common shares, totaling 570,326 shares.
Summary
- Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 570,326 common shares of MediWound Ltd.
- This represents 5.2% of MediWound's common stock, calculated based on 10,793,057 shares outstanding as of December 31, 2024.
- The aggregate beneficial ownership includes 407,061 common shares and 163,265 shares issuable upon the exercise of warrants.
- Due to a blocker provision in the warrants, the actual number of shares beneficially owned by the holder, after giving effect to such blockers, is less than the reported aggregate amount if the 9.99% ownership threshold is exceeded.
- The reporting persons have shared voting and dispositive power over 407,061 common shares.
- This filing is Amendment No. 7 to a previously filed Schedule 13G.
Sentiment
Score: 5
Explanation: This filing is a routine disclosure of beneficial ownership, providing factual information without indicating positive or negative financial performance or strategic shifts.
Positives
- The continued significant stake by an institutional investor may signal confidence in MediWound Ltd.
Risks
- Warrants contain a blocker provision that prevents exercise if it would result in beneficial ownership exceeding 9.99% of the Common Stock, potentially limiting the immediate exercisability of all warrants.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Rosalind Advisors, Inc. acts as the investment advisor to Rosalind Master Fund L.P. Steven Salamon is the President and portfolio manager of Rosalind Advisors, Inc., and Gilad Aharon is a portfolio manager and member of Rosalind Advisors, Inc. This structure defines the relationship among the reporting persons regarding the beneficial ownership.
Stakeholder Impact
- Shareholders are informed of a significant institutional holding in MediWound Ltd., providing transparency regarding major investors.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date for the outstanding shares count (10,793,057 shares) used in the percentage calculation. |
| 2025-03-19 | Date of the 20F filing from which the outstanding shares count was obtained. |
| 2025-06-30 | Date of the event which required the filing of this statement. |
| 2025-08-12 | Date this Schedule 13G Amendment No. 7 was signed and filed. |
Keywords
MediWound, MWND, Rosalind Advisors, Rosalind Master Fund, Steven Salamon, Gilad Aharon, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.